[Angiogenesis targeting in breast cancer].
Several anti-angiogenic agents are under evaluation in breast cancer. Currently, only bevacizumab has shown its efficacy, in combination with paclitaxel, on relapse-free survival in the metastatic setting. The combination of targeted therapies (for instance, trastuzumab plus bevacizumab, lapatinib plus pazopanib, etc.) is certainly of utmost interest. However, the anti-angiogenic agents not always bring in phase III the expected effects on patient survival, and an increased toxicity of combinations versus chemotherapy only has been observed. Outside the privileged neo-adjuvant setting, it appears difficult, for technical and ethical reasons, to obtain tissue samples before and after treatment to study predictive factors of drug response and to establish surrogate makers.
Fumoleau
Pierre
P
Centre Georges-François Leclerc, rue du Professeur-Marion, 21079 Dijon. PFumoleau@dijon.fnclcc.fr
Coudert
Bruno
B
Mayer
Françoise
F
Isambert
Nicolas
N
Favier
Laure
L
Ferrant
Emmanuelle
E
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000098:blood supply* / Q000191:economics; D004359:Drug Therapy, Combination; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors* / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042442:Vascular Endothelial Growth Factors; D000068258:Bevacizumab